Incyte Biosciences

Incyte is a global biopharmaceutical company headquartered in Wilmington, Delaware, dedicated to the discovery, development, and commercialization of novel therapeutics. The company is a pioneer in the field of Janus kinase (JAK) inhibition, having developed the first FDA-approved JAK inhibitor, Jakafi (ruxolitinib), for myeloproliferative neoplasms. Incyte's portfolio has since expanded into dermatology with Opzelura and oncology with several approved therapies including Pemazyre and Monjuvi. Their robust pipeline features a diverse array of small molecules and monoclonal antibodies targeting hematologic malignancies, solid tumors, and inflammatory diseases. With a strong focus on R&D and strategic global partnerships, Incyte continues to advance science to address significant unmet medical needs.